Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasinumab in chronic low back pain and osteoarthritis
NCT03285646Phase 3Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of fasinumab in chronic low back pain (CLBP), osteoarthritis (OA), sponsored by Regeneron Pharmaceuticals. Started Oct 2017; status: terminated.
02
Drugs
fasinumab
03
Conditions
chronic low back pain (CLBP)osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03285646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03285646.